Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients with Intermediate Risk RhabdomyosarcomaDecember 14, 2015 -
This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide) alternated with vincristine sulfate and irinotecan hydrochloride works compared to combination chemotherapy alternated with vincristine sulfate, irinotecan hydrochloride and temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk).
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Irinotecan hydrochloride and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy alternated with vincristine sulfate and irinotecan hydrochloride or vincristine sulfate, irinotecan hydrochloride, and temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma.
To learn more CLICK HERE.